Antonino Saitta

List of Publications by Year
in descending order

89 papers	2,735 citations	212478 28 h-index	232693 48 g-index
92 all docs	92 docs citations	92 times ranked	3884 citing authors

#	Article	IF	Citations
1	The PREdictor of MAlnutrition in Systemic Sclerosis (PREMASS) Score: A Combined Index to Predict 12 Months Onset of Malnutrition in Systemic Sclerosis. Frontiers in Medicine, 2021, 8, 651748.	1.2	7
2	Hyaluronan Fragmentation During Inflammatory Pathologies: A Signal that Empowers Tissue Damage. Mini-Reviews in Medicinal Chemistry, 2020, 20, 54-65.	1.1	23
3	Arterial stiffness improvement after adding on PCSK9 inhibitors or ezetimibe to high-intensity statins in patients with familial hypercholesterolemia: A Twoâ€“Lipid Center Real-World Experience. Journal of Clinical Lipidology, 2020, 14, 231-240.	0.6	35
4	Hyaluronan fragments produced during tissue injury: A signal amplifying the inflammatory response. Archives of Biochemistry and Biophysics, 2019, 663, 228-238.	1.4	25
5	The proteoglycan biglycan mediates inflammatory response by activating TLR-4 in human chondrocytes: Inhibition by specific siRNA and high polymerized Hyaluronan. Archives of Biochemistry and Biophysics, 2018, 640, 75-82.	1.4	19
6	Effect of type D personality on smoking status and their combined impact on outcome after acute myocardial infarction. Clinical Cardiology, 2018, 41, 321-325.	0.7	21
7	Subclinical impairment of myocardial and endothelial functionality in very early psoriatic and rheumatoid arthritis patients: Association with vitamin D and inflammation. Atherosclerosis, 2018, 271, 214-222.	0.4	30
8	Dual Î±vÎ²3 and Î±vÎ²5 blockade attenuates fibrotic and vascular alterations in a murine model of systemic sclerosis. Clinical Science, 2018, 132, 231-242.	1.8	32
9	Hyaluronan in experimental injured/inflamed cartilage: In vivo studies. Life Sciences, 2018, 193, 132-140.	2.0	21
10	Hyaluronan in the experimental injury of the cartilage: biochemical action and protective effects. Inflammation Research, 2018, 67, 5-20.	1.6	30
11	Arterial stiffness and mitral regurgitation in arterial hypertension: an intriguing pathophysiological link. Vascular Pharmacology, 2018, 111, 71-76.	1.0	4
12	O18â€ƒThe PREdictor of MAlnutrition in Systemic Sclerosis (PREMASS) score: the first validated combined index predictive of future weight loss in systemic sclerosis. Rheumatology, 2018, 57, .	0.9	0
13	Endothelial progenitor cells and rheumatic disease modifying therapy. Vascular Pharmacology, 2018, 108, 8-14.	1.0	8
14	Biglycan expression, earlier vascular damage and pro-atherogenic profile improvement after smoke cessation in young people. Atherosclerosis, 2017, 257, 109-115.	0.4	10
15	Clinical impact of angiotensin I converting enzyme polymorphisms in subjects with resistant hypertension. Molecular and Cellular Biochemistry, 2017, 430, 91-98.	1.4	6
16	CD34+ cell count predicts long lasting life in the oldest old. Mechanisms of Ageing and Development, 2017, 164, 139-145.	2.2	12
17	Current challenges on circulating progenitor cells: Could their number predict oncoming diseases?. Atherosclerosis, 2017, 261, 153-154.	0.4	0
18	Circulating progenitor cells in hypertensive subjects: Effectiveness of a treatment with olmesartan in improving cell number and miR profile in addition to expected pharmacological effects. PLoS ONE, 2017, 12, e0173030.	1.1	21

#	Article	IF	Citations
19	Endothelial Progenitor Cells for Diagnosis and Prognosis in Cardiovascular Disease. Stem Cells International, 2016, 2016, 1-12.	1.2	56
20	Venous Thromboembolism and Cerebrovascular Events in Patients with Giant Cell Arteritis: A Population-Based Retrospective Cohort Study. PLoS ONE, 2016, 11, e0149579.	1.1	18
21	Ineffective Treatment of Low-Molecular-Weight Heparin in Obese Subject with Traumatic Fractures of the Leg. International Journal of Angiology, 2016, 25, e16-e18.	0.2	3
22	Simvastatin prevents vascular complications in the chronic reactive oxygen species murine model of systemic sclerosis. Free Radical Research, 2016, 50, 514-522.	1.5	4
23	Pathophysiological mechanism and therapeutic role of S100 proteins in cardiac failure: a systematic review. Heart Failure Reviews, 2016, 21, 463-473.	1.7	27
24	Combination therapy with aliskiren versus ramipril or losartan added to conventional therapy in patients with type 2 diabetes mellitus, uncontrolled hypertension and microalbuminuria. JRAAS - Journal of the Renin-Angiotensin-Aldosterone System, 2015, 16, 956-964.	1.0	9
25	Propylthiouracil modulates aortic vasculopathy in the oxidative stress model of systemic sclerosis. Vascular Pharmacology, 2015, 71, 79-83.	1.0	7
26	Arterial stiffness as a predictor of recovery of left ventricular systolic function after acute myocardial infarction treated with primary percutaneous coronary intervention. International Journal of Cardiovascular Imaging, 2015, 31, 1545-1551.	0.7	17
27	Corrigenda. Journal of Clinical Endocrinology and Metabolism, 2015, 100, 763-763.	1.8	56
28	Vitamin D Status in Rheumatoid Arthritis: Inflammation, Arterial Stiffness and Circulating Progenitor Cell Number. PLoS ONE, 2015, 10, e0134602.	1.1	49
29	Toll-like receptor 3 and interleukin 1Î² expression in CD34+ cells from patients with rheumatoid arthritis: association with inflammation and vascular involvement. Clinical and Experimental Rheumatology, 2014, 32, 922-9.	0.4	14
30	Genistein in the Metabolic Syndrome: Results of a Randomized Clinical Trial. Journal of Clinical Endocrinology and Metabolism, 2013, 98, 3366-3374.	1.8	134
31	Left coronary artery fistula to right ventricle complicated heart failure in a patient on hemodialysis. Internal and Emergency Medicine, 2013, 8, 765-766.	1.0	28
32	Relaxin improves multiple markers of wound healing and ameliorates the disturbed healing pattern of genetically diabetic mice. Clinical Science, 2013, 125, 575-585.	1.8	43
33	Simvastatin attenuates the development of pulmonary and cutaneous fibrosis in a murine model of systemic sclerosis. Rheumatology, 2013, 52, 1377-1386.	0.9	33
34	Circulating progenitor cells and the elderly: A seven-year observational study. Experimental Gerontology, 2012, 47, 394-400.	1.2	23
35	Left Ventricular Function in Hypertension: New Insight by Speckle Tracking Echocardiography. Echocardiography, 2011, 28, 649-657.	0.3	120
36	Actinomadura pelletieri mycetoma â€“ an atypical case with spine and abdominal wall involvement. Journal of Medical Microbiology, 2011, 60, 673-676.	0.7	10

#	Article	IF	Citations
37	Circulating progenitor cells are increased in newly diagnosed untreated hypertensive patients with arterial stiffening but normal carotid intima-media thickness. Hypertension Research, 2011, 34, 876-883.	1.5	35
38	Smoke exposure and circulating progenitor cells: Evidence for modulation of antioxidant enzymes and cell count. Clinical Biochemistry, 2010, 43, 1436-1442.	0.8	40
39	Assessment of liver stiffness in subjects affected by familial combined hyperlipidaemia with hepatic steatosis. European Journal of Clinical Investigation, 2010, 40, 722-728.	1.7	16
40	Effects of the angiotensin II receptor blocker losartan on the monocyte expression of biglycan in hypertensive patients. Clinical and Experimental Pharmacology and Physiology, 2010, 37, 933-938.	0.9	28
41	Biglycan expression in hypertensive subjects with normal or increased carotid intima-media wall thickness. Clinica Chimica Acta, 2009, 406, 89-93.	0.5	28
42	Platelet activating factor-acetylhydrolase (PAF-AH) activity and HDL levels, but not PAF-AH gene polymorphisms, are associated with successful aging in Sicilian octogenarians. Aging Clinical and Experimental Research, 2008, 20, 171-177.	1.4	7
43	Tissue Factor and Monocyte Chemoattractant Protein-1 Expression in Hypertensive Individuals with Normal or Increased Carotid Intima-Media Wall Thickness. Clinical Chemistry, 2008, 54, 814-823.	1.5	25
44	Tissue factor expression and activity are not increased in peripheral monocytes isolated from uncomplicated hypertensive patients. Journal of Hypertension, 2006, 24, 731-736.	0.3	3
45	Extracellular superoxide dismutase (EC-SOD) gene mutations screening in a sample of Mediterranean population. Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 2005, 578, 143-148.	0.4	17
46	Antioxidant effect of atorvastatin is independent of PON1 gene T(â€“107)C, Q192R and L55M polymorphisms in hypercholesterolaemic patients. Current Medical Research and Opinion, 2005, 21, 777-784.	0.9	26
47	Effects of AT1 Receptor Antagonist Losartan on sICAM-1 and TNF-a Levels in Uncomplicated Hypertensive Patients. Angiology, 2004, 55, 195-203.	0.8	16
48	Platelet-Activating Factor Acetylhydrolase Is Not Associated with Carotid Intima-Media Thickness in Hypercholesterolemic Sicilian Individuals. Clinical Chemistry, 2004, 50, 2077-2082.	1.5	32
49	Identification of paraoxonase 3 gene (PON3) missense mutations in a population of southern Italy. Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 2004, 546, 75-80.	0.4	29
50	Association between serum paraoxonase (PON1) gene promoter T(-107)C polymorphism, PON1 activity and HDL levels in healthy Sicilian octogenarians. Experimental Gerontology, 2004, 39, 1089-1094.	1.2	51
51	The paraoxonase promoter polymorphism (â^'107)T>C is not associated with carotid intima-media thickness in Sicilian hypercholesterolemic patients. Clinical Biochemistry, 2004, 37, 388-394.	0.8	18
52	Effect of genistein on endothelial function in postmenopausal women: a randomized, double-blind, controlled study. American Journal of Medicine, 2003, 114, 470-476.	0.6	151
53	Effects of Atorvastatin Treatment on sICAM-1 and Plasma Nitric Oxide Levels in Hypercholesterolemic Subjects. Clinical and Applied Thrombosis/Hemostasis, 2002, 8, 257-263.	0.7	16
54	Evidence for a role of nuclear factor-ÎºB in acute hypovolemic hemorrhagic shock. Surgery, 2002, 131, 50-58.	1.0	27

#	Article	IF	Citations
55	Effects of simvastatin treatment on sICAM-1 and sE-selectin levels in hypercholesterolemic subjects. Atherosclerosis, 2001, 155, 143-147.	0.4	34
56	Which patients with cirrhosis should undergo endoscopic screening for esophageal varices detection?. Hepatology, 2001, 33, 333-338.	3.6	248
57	The Phytoestrogen Î±-Zearalenol Reverses Endothelial Dysfunction Induced by Oophorectomy in Rats. Laboratory Investigation, 2001, 81, 125-132.	1.7	21
58	Oxidative stress causes nuclear factor-ÎºB activation in acute hypovolemic hemorrhagic shock. Free Radical Biology and Medicine, 2001, 30, 1055-1066.	1.3	67
59	Cardiovascular Effects of Raloxifene Hydrochloride. Cardiovascular Drug Reviews, 2001, 19, 57-74.	4.4	45
60	Protective effects of Cyclosporin-A in splanchnic artery occlusion shock. British Journal of Pharmacology, 2000, 130, 339-344.	2.7	10
61	Tacrolimus Limits Polymorphonuclear Leucocyte Accumulation and Protects Against Myocardial Ischaemiaâ€“ Reperfusion Injury. Journal of Molecular and Cellular Cardiology, 2000, 32, 429-440.	0.9	45
62	Effects of Fluvastatin Treatment on Red Blood Cell Na+ Transport Systems in Hypercholesterolemic Subjects. Journal of Cardiovascular Pharmacology, 2000, 35, 376-382.	0.8	6
63	Recombinant human erythropoietin inhibits iNOS activity and reverts vascular dysfunction in splanchnic artery occlusion shock. British Journal of Pharmacology, 1999, 127, 482-488.	2.7	64
64	Tacrolimus suppresses tumour necrosis factor-Î± and protects against splanchnic artery occlusion shock. British Journal of Pharmacology, 1999, 127, 498-504.	2.7	14
65	Adrenocorticotropin reverses vascular dysfunction and protects against splanchnic artery occlusion shock. British Journal of Pharmacology, 1999, 128, 816-822.	2.7	31
66	Cardioprotection by the phytoestrogen genistein in experimental myocardial ischaemia-reperfusion injury. British Journal of Pharmacology, 1999, 128, 1683-1690.	2.7	87
67	Cyclosporin-A reduces leukocyte accumulation and protects against myocardial ischaemia reperfusion injury in rats. European Journal of Pharmacology, 1999, 364, 159-168.	1.7	44
68	The lazaroid, U-74389G, inhibits inducible nitric oxide synthase activity, reverses vascular failure and protects against endotoxin shock. European Journal of Pharmacology, 1999, 369, 49-55.	1.7	23
69	Effect of sulfatide on acute lung injury during endotoxemia in rats. Life Sciences, 1999, 65, 2541-2552.	2.0	8
70	Inhibition of tumour necrosis factor and reversal of endotoxin-induced shock by U-83836E, a â€˜second generationâ€™ lazaroid in rats. British Journal of Pharmacology, 1998, 124, 1293-1299.	2.7	15
71	Sulfatide reduces leucocyte accumulation and reverts vascular failure in splanchnic artery occlusion shock. European Journal of Pharmacology, 1998, 361, 101-108.	1.7	2
72	Protective Effects of the New Lazaroid â€œU-83836Eâ€•in Splanchnic Artery Occlusion (SAO) Shock. Free Radical Research, 1998, 28, 477-484.	1.5	8

#	Article	IF	Citations
73	17Î²-oestradiol reduces cardiac leukocyte accumulation in myocardial ischaemia reperfusion injury in rat. European Journal of Pharmacology, 1997, 335, 185-192.	1.7	98
74	The effects of recombinant human granulocyte-colony stimulating factor on vascular dysfunction and splanchnic ischaemia-reperfusion injury. British Journal of Pharmacology, 1997, 120, 333-339.	2.7	28
75	The involvement of tumour necrosis factor-Î± in the protective effects of 17Î² oestradiol in splanchnic ischaemia-reperfusion injury. British Journal of Pharmacology, 1997, 121, 1782-1788.	2.7	20
76	Effects of Sâ€ethylisothiourea, a potent inhibitor of nitric oxide synthase, alone or in combination with a nitric oxide donor in splanchnic artery occlusion shock. British Journal of Pharmacology, 1996, 119, 23-28.	2.7	10
77	Leukocyte integrin very late antigen-4/vascular cell adhesion molecule-1 adhesion pathway in splanchnic artery occlusion shock. European Journal of Pharmacology, 1996, 318, 153-160.	1.7	3
78	Effects of gallopamil on epinephrine and norepinephrine plasmatic levels and on txb2 and beta-tg release in patients with coronary artery disease during adrenergic stimulus with cold pressor test. Pharmacological Research, 1995, 32, 49-55.	3.1	0
79	Improved survival and reversal of endothelial dysfunction by the 21â€aminosteroid, Uâ€74389G in splanchnic ischaemiaâ€reperfusion injury in the rat. British Journal of Pharmacology, 1995, 115, 395-400.	2.7	27
80	Antibodies against intercellular adhesion molecule 1 protect against myocardial ischaemia-reperfusion injury in rat. European Journal of Pharmacology, 1994, 264, 143-149.	1.7	35
81	Contribution of intercellular adhesion molecule 1 (ICAMâ€1) to the pathogenesis of splanchnic artery occlusion shock in the rat. British Journal of Pharmacology, 1994, 113, 912-916.	2.7	22
82	Participation of tumour necrosis factor and nitric oxide in the mediation of vascular dysfunction in splanchnic artery occlusion shock. British Journal of Pharmacology, 1994, 113, 1153-1158.	2.7	33
83	Isodicentric Philadelphia chromosome in accelerated phase of chronic myeloid leukemia. Cancer Genetics and Cytogenetics, 1993, 66, 113-116.	1.0	9
84	G 619, a Dual Thromboxane Synthase Inhibitor and Thromboxane A₂ Receptor Antagonist, Reduces Myocardial Damage and Polymorpho-nuclear Leukocyte Accumulation following Coronary Artery Occlusion and Reperfusion in Rats. Pharmacology, 1993, 47, 167-175.	0.9	8
85	Protective Effects of G 619, a Dual Thromboxane Synthase Inhibitor and Thromboxane A2 Receptor Antagonist, in Splanchnic Artery Occlusion Shock. Journal of Cardiovascular Pharmacology, 1992, 19, 115-119.	0.8	14
86	Evidence for a Role of Nitric Oxide in Hypovolemic Hemorrhagic Shock. Journal of Cardiovascular Pharmacology, 1992, 19, 982-986.	0.8	67
87	Cloricromene, a coumarine derivative, protects against lethal endotoxin shock in rats. European Journal of Pharmacology, 1992, 210, 107-113.	1.7	28
88	Serum activity of beta-N-acetylglucosaminidase in obese hyperinsulinemic subjects. Acta Diabetologica Latina, 1985, 22, 247-252.	0.2	2
89	Serum and urinary activities of beta-N-acetylglucosaminidase and beta-glucuronidase in diabetic patients. Acta Diabetologica Latina, 1983, 20, 257-264.	0.2	11